GlaxoSmithKlineGlaxoSmithKline Corporate and Social Responsibility Report 2002
Reporting Front PageDownloads
CSR 2002 home
A global challenge
The scope of our business
Our contribution to society
Medicines for the developing world
Community investment
Research & development
Valuing people
Case study
Environment, health and safety
Business ethics and integrity
Management of CSR
Web references
Corporate Social Responsibility Committee

GSK employs over 100,000 people and operates in more than 150 countries.
People are the greatest single source of competitive advantage for any company. At GlaxoSmithKline, we believe that attracting, retaining and motivating the very best people is the foundation for our future success.
Valuing people
Previous
Next
 

We are committed to providing the opportunity for our employees to do meaningful and challenging work in pursuit of our goal to improve the quality of human life by enabling people to do more, feel better and live longer.

Last year we reported on the principles that underpin our approach to people management, and a range of programmes which were designed to deliver our global human resources strategy. We are now pleased to report the progress we have made and set out, where we are able, how we intend in future to measure our performance on issues such as diversity.

THE GSK CULTURE
At GSK, great emphasis is placed not only on what we must achieve as a company, but also on how we deliver our achievements. Our culture is summed up in the GSK Spirit which defines the qualities we expect all our employees to embrace:

  • performance with integrity
  • entrepreneurial spirit
  • focus on innovation
  • a sense of urgency
  • passion for achievement

Developing the GSK culture is critical to enabling people to reach their potential and do their best work. We therefore carried out a survey in 2002 of 10,000 managers to assess how well the Spirit and culture is being adopted. We sought views on the experience of working for GSK, including both what managers considered was being done well and what areas needed further work.

The survey results were generally very positive, showing that managers take great pride in being part of GSK. For example, there was overwhelming support for the statements that “people in my department show commitment to performance with integrity”, “my department is a focused organisation with a sense of urgency” and “I would gladly refer a good friend or family member to GSK for employment”. These findings show that managers believe that the GSK Spirit is reflected in the way they and others are working day to day.

The results also raised important areas for further development. These included concerns about whether people are able to perform to their full potential, the extent to which managers are able to act as coaches to support development, and the degree of staff involvement in decisions that affect their work. These issues are all being addressed by GSK’s Corporate Executive Team. For example, a programme has been put in place to reduce complexity and bureaucracy in the company and to streamline processes to help free up managers to do their best work.

The survey results were generally very positive, showing that managers take great pride in being part of GSK.

Chart: Ethnicity of US Employee Population, 2002DIVERSITY
Diversity is a business imperative for GSK; we are committed to the principles of equality of opportunity and equal treatment. We aim to have a workforce and working environment that reflects the diversity of background, culture, beliefs and characteristics of the communities in which we operate.

We are therefore embedding the values of diversity and equal treatment into our key business processes. For employees, this means that diversity measures are included in manager and employee training, external recruitment and internal appointment processes, performance assessments and pay reviews, succession planning and developmental assignments.

For customers and stakeholders, it includes the development of measures to reach targeted customers, outreach programmes for specific patient groups and advertising that reflects the many communities we serve.

We are fundamentally committed to the principles of equality of opportunity and equal treatment.

We believe that our diversity strategy will show clear progress against the baseline figures we report this year (see below). We will report changes annually.

Global Senior Management population by gender 2002

With the exception of the US (see ethnicity chart), we do not have meaningful data on the ethnicity of our employees because of the different ways ethnic groups are described in different countries and, in some cases, because of legal restrictions on collecting these data.

HUMAN RIGHTS
GSK believes that on human rights issues, we can lead by example and thereby influence the behaviours and practices of others through clear demonstration of our own values. Our most effective contribution can be made through pursuing policies in our own operations that respect the rights and interests of all those affected by and involved in our business. GSK supports and is committed to upholding the United Nations Universal Declaration of Human Rights26 and the core labour standards set out by the International Labour Organization27.

During 2002, we carried out an internal review which demonstrated that, wherever we operate as an employer, we believe we are complying with the Universal Declaration of Human Rights and the core conventions of the International Labour Organization, and according to the Guidelines for Multinational Enterprises set by the OECD 28. Conducted through the Head of Human Resources for each country, the review was also used to build awareness and understanding of human rights issues.

Also during the year, we began to put in place binding requirements to ensure that our major contractors and suppliers adopt GSK’s standards on human rights and core labour standards.

Web references


26

www.un.org/Overview/rights.html
27 www.ilo.org/public/english/standards/decl/declaration/text/index.htm
28 www.oecd.org/pdf/M000015000/M00015419.pdf

 

Previous
Next


Top


CSR 2002 Home | Reporting Front Page | Downloads | Main Site

 
Updated March 28, 2003 - © 2005 GlaxoSmithKline - All Rights Reserved
Legal Notices - Privacy Statement